(HLUN-A) H Lundbeck - Ratings and Ratios
Psychiatric, Neurological, Pharmaceuticals, Medications, Treatments
HLUN-A EPS (Earnings per Share)
HLUN-A Revenue
Description: HLUN-A H Lundbeck
H. Lundbeck A/S is a pharmaceutical company specializing in treatments for psychiatric and neurological disorders. The companys product portfolio includes established medications such as Abilify Maintena/Abilify Asimtufii for schizophrenia and bipolar disorder, Brintellix/Trintellix for depression, and Vyepti for migraine prevention. Additionally, Lundbeck offers treatments for various conditions, including epilepsy, dementia, Parkinsons disease, and chorea.
Lundbecks pipeline includes several promising candidates in various stages of clinical trials, focusing on migraine prevention, cluster headache, neurohormonal dysfunctions, post-traumatic stress disorder, Parkinsons disease, and developmental and epileptic encephalopathies. Notable candidates include Eptinezumab, Lu AG09222, Lu AG13909, Brexpiprazole, Lu AF28996, Bexicaserin, Amlenetug, and Lu AG22515. The companys research and development efforts are focused on addressing significant unmet medical needs in the neurology and psychiatry spaces.
From a financial perspective, key performance indicators (KPIs) such as revenue growth, R&D expenditure as a percentage of revenue, and pipeline progression are crucial in evaluating Lundbecks performance. With a market capitalization of approximately 34.8 billion DKK, Lundbecks market presence is substantial. The companys price-to-earnings (P/E) ratio of 9.22 and forward P/E of 7.87 suggest relatively attractive valuation compared to peers. Return on Equity (RoE) of 13.61% indicates a decent return on shareholders equity.
To further analyze Lundbecks potential, its essential to examine its revenue breakdown by product, geographic region, and the competitive landscape. The companys ability to successfully commercialize its existing products and bring new pipeline candidates to market will be critical in driving future growth. Additionally, monitoring Lundbecks cash position, debt levels, and operating cash flows will provide insights into its financial health and ability to fund R&D initiatives.
HLUN-A Stock Overview
| Market Cap in USD | 6,087m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
HLUN-A Stock Ratings
| Growth Rating | -11.3% |
| Fundamental | 66.7% |
| Dividend Rating | 59.2% |
| Return 12m vs S&P 500 | -29.5% |
| Analyst Rating | - |
HLUN-A Dividends
| Dividend Yield 12m | 2.90% |
| Yield on Cost 5y | 3.25% |
| Annual Growth 5y | 9.86% |
| Payout Consistency | 100.0% |
| Payout Ratio | 27.0% |
HLUN-A Growth Ratios
| Growth Correlation 3m | 48.8% |
| Growth Correlation 12m | -72.4% |
| Growth Correlation 5y | 45.1% |
| CAGR 5y | 4.36% |
| CAGR/Max DD 5y | 0.10 |
| CAGR/Mean DD 5y | 0.21 |
| Sharpe Ratio 12m | -0.13 |
| Alpha | -35.15 |
| Beta | 0.952 |
| Volatility | 29.19% |
| Current Volume | 40.7k |
| Average Volume 20d | 53k |
| Stop Loss | 32.5 (-3.3%) |
| Signal | -0.16 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (3.48b TTM) > 0 and > 6% of Revenue (6% = 1.41b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -5.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 19.07% (prev 34.38%; Δ -15.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 3.41b <= Net Income 3.48b (YES >=105%, WARN >=100%) |
| Net Debt (10.54b) to EBITDA (3.44b) ratio: 3.06 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.59 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (991.9m) change vs 12m ago 0.48% (target <= -2.0% for YES) |
| Gross Margin 81.55% (prev 78.43%; Δ 3.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.76% (prev 52.95%; Δ -1.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 30.44 (EBITDA TTM 3.44b / Interest Expense TTM 113.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.45
| (A) 0.09 = (Total Current Assets 12.02b - Total Current Liabilities 7.54b) / Total Assets 51.80b |
| (B) 0.45 = Retained Earnings (Balance) 23.51b / Total Assets 51.80b |
| (C) 0.08 = EBIT TTM 3.44b / Avg Total Assets 45.45b |
| (D) 0.85 = Book Value of Equity 23.51b / Total Liabilities 27.61b |
| Total Rating: 3.45 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.74
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 5.03% = 2.51 |
| 3. FCF Margin 12.12% = 3.03 |
| 4. Debt/Equity 0.86 = 2.15 |
| 5. Debt/Ebitda 6.02 = -2.50 |
| 6. ROIC - WACC 1.64% = 2.05 |
| 7. RoE 14.28% = 1.19 |
| 8. Rev. Trend 94.56% = 4.73 |
| 9. Rev. CAGR 9.28% = 1.16 |
| 10. EPS Trend 20.62% = 0.52 |
| 11. EPS CAGR 14.04% = 1.40 |
What is the price of HLUN-A shares?
Over the past week, the price has changed by +0.60%, over one month by +13.32%, over three months by +2.13% and over the past year by -15.23%.
Is H Lundbeck a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HLUN-A is around 31.31 DKK . This means that HLUN-A is currently overvalued and has a potential downside of -6.82%.
Is HLUN-A a buy, sell or hold?
What are the forecasts/targets for the HLUN-A price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 34.2 | 1.9% |
HLUN-A Fundamental Data Overview
Market Cap DKK = 38.62b (38.62b DKK * 1.0 DKK.DKK)
CCE Cash And Equivalents = 2.65b DKK (Cash only, last quarter)
P/E Trailing = 9.5313
P/E Forward = 8.0841
P/S = 1.642
P/B = 1.3758
P/EG = 6.512
Beta = 0.301
Revenue TTM = 23.52b DKK
EBIT TTM = 3.44b DKK
EBITDA TTM = 3.44b DKK
Long Term Debt = 13.19b DKK (from longTermDebt, last quarter)
Short Term Debt = 7.54b DKK (from totalCurrentLiabilities, last quarter)
Debt = 20.72b DKK (Calculated: Short Term 7.54b + Long Term 13.19b)
Net Debt = 10.54b DKK (from netDebt column, last quarter)
Enterprise Value = 56.70b DKK (38.62b + Debt 20.72b - CCE 2.65b)
Interest Coverage Ratio = 30.44 (Ebit TTM 3.44b / Interest Expense TTM 113.0m)
FCF Yield = 5.03% (FCF TTM 2.85b / Enterprise Value 56.70b)
FCF Margin = 12.12% (FCF TTM 2.85b / Revenue TTM 23.52b)
Net Margin = 14.82% (Net Income TTM 3.48b / Revenue TTM 23.52b)
Gross Margin = 81.55% ((Revenue TTM 23.52b - Cost of Revenue TTM 4.34b) / Revenue TTM)
Tobins Q-Ratio = 2.41 (Enterprise Value 56.70b / Book Value Of Equity 23.51b)
Interest Expense / Debt = 0.55% (Interest Expense 113.0m / Debt 20.72b)
Taxrate = 15.49% (576.0m / 3.72b)
NOPAT = 2.91b (EBIT 3.44b * (1 - 15.49%))
Current Ratio = 1.59 (Total Current Assets 12.02b / Total Current Liabilities 7.54b)
Debt / Equity = 0.86 (Debt 20.72b / last Quarter total Stockholder Equity 24.19b)
Debt / EBITDA = 6.02 (Net Debt 10.54b / EBITDA 3.44b)
Debt / FCF = 7.27 (Debt 20.72b / FCF TTM 2.85b)
Total Stockholder Equity = 24.40b (last 4 quarters mean)
RoA = 6.73% (Net Income 3.48b, Total Assets 51.80b )
RoE = 14.28% (Net Income TTM 3.48b / Total Stockholder Equity 24.40b)
RoCE = 9.15% (Ebit 3.44b / (Equity 24.40b + L.T.Debt 13.19b))
RoIC = 8.00% (NOPAT 2.91b / Invested Capital 36.34b)
WACC = 6.36% (E(38.62b)/V(59.34b) * Re(9.52%)) + (D(20.72b)/V(59.34b) * Rd(0.55%) * (1-Tc(0.15)))
Shares Correlation 5-Years: -97.50 | Cagr: -0.06%
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.79% ; FCFE base≈3.36b ; Y1≈4.15b ; Y5≈7.08b
Fair Price DCF = 464.7 (DCF Value 92.38b / Shares Outstanding 198.8m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 94.56 | Revenue CAGR: 9.28%
Rev Growth-of-Growth: 5.04
EPS Correlation: 20.62 | EPS CAGR: 14.04%
EPS Growth-of-Growth: 25.30